Compare Air Products & Chemicals, Inc. (APD) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Heron Therapeutics Inc — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.63B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Air Products & Chemicals, Inc. is far larger — about 1082.3× Heron Therapeutics Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.35% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| APD | HRTX | |
|---|---|---|
Market Cap | $68.63B | $63.41M |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $1.49 |
52-Week Low | $230.42 | $0.32 |
Enterprise Value | $85.80B | $161.31M |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Air Products and Chemicals (APD) trades at $303.44, up 1.17% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows strong analyst support with a consensus price target of $346, though high valuation ratios like a P/E of 30.86 and EV/EBITDA of 50.36 raise concerns. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance after Q3 2026 results.
The outlook is mixed: positive momentum from contract wins and earnings performance offers upside, but negative net income margins and elevated debt levels pose risks. Investors should weigh growth catalysts against financial leverage and profitability challenges.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
